These findings confirm that SOAT is a critical upstream regulator of intracrine estrogen biosynthesis in breast cancer cells and highlight compounds 12 and 24 as promising candidates for further preclinical development aimed at reducing local estrogen production. This evidence concerns the gene SLC10A6 and breast cancer.